Oncology Trials Lead: Solid Tumor Medical Director (Remote)

Medpace; England; Hybrid; GBP 120.000 - 180.000; Vollzeit

Benefits dieser Stelle

Flexible work environment

Competitive compensation and benefits

Competitive PTO

Structured career paths

Company-sponsored events

Employee wellness initiatives

Zusammenfassung

Medpace is seeking an Oncologist - Solid Tumor Medical Director in the UK to provide medical, scientific, and strategic leadership for clinical trials. You will act as the internal medical expert for review and interpretation of results in clinical study reports, contribute to study design and project plans, and drive new clinical projects.

Hybrid WFH flexibility is available. Travel up to 20% is expected as part of cross-site collaboration and sponsor meetings.

Qualifikationen

• MD degree or equivalent required; board certification and licensure preferred.
• Prior clinical trial research experience preferred.
• Experience in pharmaceutical-related clinical research is preferred.

Aufgaben

• Provide medical management and expertise for clinical trials.
• Contribute medical expertise to study reports, regulatory documents, and manuscripts.
• Manage safety issues in clinical trials and collaborate with evaluation teams.
• Participate in new business development through sponsor meetings and proposals.
• Coordinate with departments across all study phases, including feasibility, design, and medical writing.
• Lead adherence to research protocols and policies.

Kenntnisse

Medical leadership

Clinical trial expertise

Oncology

Regulatory understanding

Proposal development

Ausbildung

MD degree

Jobbeschreibung

Medpace is seeking an Oncologist - Solid Tumor Medical Director in the UK to provide medical, scientific, and strategic leadership for clinical trials. You will act as the internal medical expert for review and interpretation of results in clinical study reports, contribute to study design and project plans, and drive new clinical projects.

Hybrid WFH flexibility is available. Travel up to 20% is expected as part of cross-site collaboration and sponsor meetings.